See more : Zanite Acquisition Corp. (ZNTEU) Income Statement Analysis – Financial Results
Complete financial analysis of Heron Therapeutics, Inc. (HRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Via Renewables, Inc. (VIA) Income Statement Analysis – Financial Results
- Primerica, Inc. (PRI) Income Statement Analysis – Financial Results
- M1 Kliniken AG (MKLNF) Income Statement Analysis – Financial Results
- Projektengagemang Sweden AB (publ) (PENG-B.ST) Income Statement Analysis – Financial Results
- The Indian Card Clothing Company Limited (INDIANCARD.NS) Income Statement Analysis – Financial Results
Heron Therapeutics, Inc. (HRTX)
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.04M | 107.67M | 86.35M | 88.64M | 145.97M | 77.47M | 30.77M | 1.28M | 0.00 | 0.00 | 0.00 | 0.00 | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.82M | 4.39M | 3.37M | 20.40M | 20.00M | 18.30M | 18.70M | 16.10M | 15.90M | 19.90M | 7.30M | 2.80M | 2.40M | 2.80M | 2.50M | 1.70M |
| Cost of Revenue | 65.11M | 54.87M | 46.02M | 36.19M | 61.62M | 27.51M | 4.59M | 35.00K | 734.00K | 54.83M | 30.92M | 14.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 445.00K | 440.27K | 613.20K | 6.40M | 5.70M | 6.00M | 9.40M | 9.80M | 9.00M | 11.60M | 3.80M | 1.10M | 1.20M | 700.00K | 600.00K | 400.00K |
| Gross Profit | 61.94M | 52.80M | 40.33M | 52.45M | 84.35M | 49.96M | 26.18M | 1.24M | -734.00K | -54.83M | -30.92M | -14.08M | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.37M | 3.95M | 2.75M | 14.00M | 14.30M | 12.30M | 9.30M | 6.30M | 6.90M | 8.30M | 3.50M | 1.70M | 1.20M | 2.10M | 1.90M | 1.30M |
| Gross Profit Ratio | 48.75% | 49.04% | 46.70% | 59.17% | 57.79% | 64.49% | 85.09% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 92.35% | 89.96% | 81.78% | 68.63% | 71.50% | 67.21% | 49.73% | 39.13% | 43.40% | 41.71% | 47.95% | 60.71% | 50.00% | 75.00% | 76.00% | 76.47% |
| Research & Development | 55.90M | 107.51M | 130.82M | 174.53M | 167.38M | 140.03M | 138.58M | 103.13M | 61.18M | 54.83M | 32.78M | 15.05M | 8.21M | 7.26M | 7.80M | 19.51M | 19.36M | 15.24M | 10.30M | 11.50M | 8.66M | 6.70M | 7.35M | 3.71M | 4.30M | 4.40M | 3.70M | 3.50M | 4.10M | 6.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 49.01M | 37.44M | 40.15M | 42.23M | 37.90M | 29.26M | 25.55M | 21.37M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 67.64M | 82.51M | 87.18M | 63.85M | 89.76M | 64.60M | 56.60M | 47.67M | 17.35M | 8.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.66M | 119.95M | 127.33M | 106.08M | 127.66M | 93.87M | 82.16M | 69.03M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 8.50M | 17.50M | 8.80M | 4.90M | 5.10M | 6.70M | 6.90M | 4.50M |
| Other Expenses | 0.00 | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -38.00K | -2.23M | -666.00K | -1.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| Operating Expenses | 172.55M | 227.46M | 258.15M | 280.61M | 295.04M | 233.90M | 220.74M | 172.16M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.19M | 10.65M | 7.06M | 11.30M | 11.80M | 12.30M | 16.30M | 14.90M | 15.90M | 18.70M | 9.90M | 5.70M | 5.90M | 7.40M | 7.80M | 5.40M |
| Cost & Expenses | 237.66M | 282.33M | 304.17M | 316.80M | 356.66M | 261.41M | 225.33M | 172.19M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.64M | 11.09M | 7.67M | 17.70M | 17.50M | 18.30M | 25.70M | 24.70M | 24.90M | 30.30M | 13.70M | 6.80M | 7.10M | 8.10M | 8.40M | 5.80M |
| Interest Income | 3.36M | 1.64M | 433.00K | 3.63M | 7.26M | 5.97M | 1.05M | 445.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 587.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.87M | 2.47M | 2.41M | 1.90M | 1.47M | 2.67M | 3.94M | 2.66M | 958.00K | 887.00K | 826.00K | 599.00K | 373.00K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.90M | 2.89M | 3.02M | 2.85M | 2.04M | 1.51M | 1.53M | 1.10M | 734.00K | 578.00K | 333.00K | 197.00K | 179.00K | 227.00K | 356.00K | 412.00K | 289.00K | -244.00K | 446.00K | 314.00K | 460.00K | 482.00K | 406.06K | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| EBITDA | -103.79M | -176.66M | -215.25M | -222.53M | -201.23M | -174.66M | -192.02M | -169.38M | -96.19M | -73.98M | -54.46M | -23.83M | -10.88M | -6.97M | -9.86M | -22.51M | -19.44M | 5.91M | -8.03M | -9.02M | -5.96M | -4.58M | -6.77M | -4.03M | -1.50M | -2.00M | -800.00K | -7.10M | -7.40M | -7.90M | -9.20M | -5.30M | -3.20M | -3.90M | -4.60M | -5.00M | -3.20M |
| EBITDA Ratio | -81.70% | -162.21% | -252.27% | -257.41% | -142.94% | -237.42% | -624.10% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,684.67% | -956.73% | -783.58% | -6,223.85% | -6,274.51% | 0.00% | -148.95% | -166.99% | -130.05% | -75.84% | -145.49% | -132.20% | 15.69% | 18.50% | 4.92% | -24.06% | -44.72% | -47.80% | -50.75% | -83.56% | -128.57% | -204.17% | -196.43% | -244.00% | -217.65% |
| Operating Income | -110.62M | -174.66M | -217.83M | -228.16M | -210.69M | -183.94M | -194.56M | -170.92M | -96.93M | -74.56M | -54.46M | -23.83M | -11.06M | -9.93M | -10.24M | -23.45M | -23.63M | -18.86M | -8.47M | -9.32M | -6.61M | -4.82M | -6.70M | -4.31M | 2.70M | 2.50M | -300.00K | -7.00M | -8.60M | -9.00M | -10.40M | -6.40M | -4.00M | -4.70M | -5.30M | -5.90M | -4.10M |
| Operating Income Ratio | -87.07% | -162.21% | -252.27% | -257.41% | -144.34% | -237.42% | -632.36% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,712.38% | -763.57% | -812.21% | -6,353.66% | -5,736.17% | 0.00% | -157.17% | -172.39% | -136.39% | -82.96% | -152.79% | -127.96% | 13.24% | 12.50% | -1.64% | -37.43% | -53.42% | -56.60% | -52.26% | -87.67% | -142.86% | -195.83% | -189.29% | -236.00% | -241.18% |
| Total Other Income/Expenses | 56.00K | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -2.93M | -2.23M | -666.00K | -1.81M | -826.00K | -599.00K | -373.00K | 2.74M | 24.00K | 520.00K | 3.83M | 24.38M | 290.00K | 224.00K | 153.00K | 297.00K | 712.64K | 26.39K | 0.00 | 200.00K | 300.00K | 400.00K | -200.00K | -300.00K | 900.00K | 600.00K | 0.00 | 1.00M | 900.00K | 1.10M | 500.00K |
| Income Before Tax | -110.56M | -182.02M | -220.68M | -227.28M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -24.43M | -11.44M | -7.20M | -10.15M | -23.13M | -19.80M | 5.52M | -8.47M | -9.29M | -6.46M | -4.76M | -6.62M | -4.28M | 0.00 | 2.70M | 0.00 | -8.10M | -8.80M | -9.30M | -9.50M | -5.80M | -4.00M | -3.70M | -4.40M | -4.80M | -3.60M |
| Income Before Tax Ratio | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,770.12% | -553.11% | -804.92% | -6,266.94% | -4,805.83% | 0.00% | -157.11% | -171.98% | -133.23% | -81.79% | -150.83% | -127.18% | 0.00% | 13.50% | 0.00% | -43.32% | -54.66% | -58.49% | -47.74% | -79.45% | -142.86% | -154.17% | -157.14% | -192.00% | -211.76% |
| Income Tax Expense | 0.00 | -47.51M | -3.02M | -2.85M | 1.87M | 7.77M | 3.90M | -1.10M | -734.00K | -578.00K | -333.00K | -1.28M | 379.00K | -2.59M | -122.00K | -320.00K | 41.00K | 119.00K | -263.00K | -95.00K | -2.25M | -1.05M | -4.19M | -12.86M | 300.00K | 600.00K | 700.00K | 2.40M | 800.00K | 800.00K | -500.00K | -200.00K | 300.00K | -800.00K | -800.00K | -900.00K | -300.00K |
| Net Income | -110.56M | -134.52M | -217.66M | -224.43M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -23.35M | -11.81M | -7.35M | -10.03M | -23.13M | -20.16M | 5.27M | -8.21M | -9.22M | -4.36M | -3.78M | -2.51M | 8.55M | 2.40M | 1.90M | -700.00K | -9.40M | -9.40M | -9.80M | -9.90M | -5.60M | -4.30M | -3.90M | -4.50M | -5.00M | -3.80M |
| Net Income Ratio | -87.02% | -124.93% | -252.08% | -253.20% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,828.79% | -564.64% | -795.24% | -6,266.94% | -4,893.93% | 0.00% | -152.29% | -170.63% | -90.00% | -64.97% | -57.29% | 254.09% | 11.76% | 9.50% | -3.83% | -50.27% | -58.39% | -61.64% | -49.75% | -76.71% | -153.57% | -162.50% | -160.71% | -200.00% | -223.53% |
| EPS | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.70 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 10.40 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| EPS Diluted | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.25 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 9.60 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| Weighted Avg Shares Out | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 78.95K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.24K | 250.99K | 248.18K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
| Weighted Avg Shares Out (Dil) | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 79.49K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.43K | 253.15K | 254.76K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
Heron Therapeutics Announces $30 Million Private Placement Financing
SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has entered...
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.63 per share a year ago.
Why Heron Therapeutics Stock Has Been on Fire This Week
Monday, Heron announced the appointment of Craig Collard as Chief Executive Officer and Adam Morgan as Chairman. These two executives will replace outgoing CEO and Chairman Barry Quart.
Why Shares of Heron Therapeutics Jumped Thursday
Heron's cash position remains a concern. Zynrelef, the company's top-selling therapy for postoperative pain relief, had 2022 sales that were up 362%.
Heron Therapeutics, Inc. (HRTX) Q4 2022 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chairman and Chief Executive Officer John Poyhonen – President and...
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023
SAN DIEGO , March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...
Best Penny Stocks This Week? 4 Short Squeeze Stocks To Watch
Short interest is high on these penny stocks. Time to buy or avoid them entirely?
10 Top Penny Stocks To Watch With High Short Interest This Week
Short squeeze penny stocks to buy now or avoid entirely? The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy Now? 6 Short Squeeze Stocks To Watch
Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?
Source: https://incomestatements.info
Category: Stock Reports